Dr. Joel MD

Dr. Joel MD Founder & CEO at Healthspan By Design & Emergency Medicine Physician

https://patient.healthspanbydesign.co/goals

04/29/2026

04/28/2026

Patients ask me about peptides every week. BPC-157. TB-500. Ipamorelin. The list keeps growing.
Before I’d ever recommend one or take it myself it has to pass 4 questions:

Do we know how it actually works in the human body?
Has it been proven in real humans, not rats or cells?
Do we know the right dose from actual studies?
Do we know it’s safe long-term?

Semaglutide (Ozempic, Wegovy) passes. Most of what’s being marketed online doesn’t come close.
If you can’t answer all 4 you’re not on a treatment.
You’re running an experiment on yourself.

Save this. Send it to the friend who’s about to start.

Visit healthspanbydesign.co if you want to learn how to truly optimize your health

04/27/2026

Peptides aren’t the problem.

👉 Bad evidence is.

There are peptide-based drugs that are well-studied and widely used—like
Semaglutide—with strong human data and known safety.

Then there are the peptides most people are talking about online.

And those typically have:
• no high-quality human trials
• no long-term safety data
• no validated dosing

A common argument is:
👉 “They aren’t being studied because they can’t be patented.”

That’s simply not true.

Most peptides—whether approved or experimental—are not in their natural form.

👉 They are analogs.

They’ve been:
• modified
• stabilized
• engineered

And that makes them:
👉 patentable
👉 scalable
👉 profitable

So if one of these peptides truly delivered consistent, meaningful results…

👉 pharma would be all over it

That’s not speculation—that’s how the system works.

So when something remains in the gray zone for years…

👉 the more likely explanation is that it hasn’t held up when tested

Not that it’s being ignored.

04/22/2026

Hormone optimization isn’t about guessing. It’s about precision.

Estradiol, progesterone, metabolic markers… they all matter.
And they all need to be interpreted in context.

No generic protocols. No one-size-fits-all plans.

If you want a personalized, data-driven approach to your hormones:

Healthspanbydesign.co

04/13/2026
04/01/2026

A zero coronary artery calcium (CAC) score does NOT mean zero risk.

CAC detects calcified (stable) plaque—often a later-stage finding. The plaques that rupture and cause heart attacks are typically non-calcified (soft plaque), which CAC does not detect.

LDL = cholesterol content
ApoB = number of atherogenic particles (better predictor of risk)

Think: ApoB = number of particles driving plaque formation over time.

Even with CAC = 0, long-term exposure to elevated ApoB can still lead to plaque buildup and future events.

If you want help optimizing your numbers visit → Healthspanbydesign.co

Sources:
Sniderman AD et al. Circulation (2019)
Ference BA et al. European Heart Journal (2017)
Budoff MJ et al. JACC (2018)

Entrenando duro porque este año hay boda 😆🙈👰🏽🤵🏻‍♂️🤞🏽 💒💍Your longevity Doctor & your Registered Dietitan practice what th...
01/09/2026

Entrenando duro porque este año hay boda 😆🙈👰🏽🤵🏻‍♂️🤞🏽 💒💍

Your longevity Doctor & your Registered Dietitan practice what they preach 🩺🥗

01/07/2026

The new Dietary Guidelines push more animal foods and higher protein intake.
Some of that makes sense.

But the same guidelines still recommend keeping saturated fat under 10% of total calories, which is very hard to do on a diet built around steak, eggs, whole milk, butter, and full-fat dairy.

Saturated fat adds up quickly.
Excess intake raises LDL and ApoB, and elevated ApoB is causal for cardiovascular disease.

Eating more quality protein is a good idea.
But what you choose matters if you want to reduce long-term risk.

When nutrition advice sends mixed signals, the math needs to be explained clearly, not brushed off as “old dogma.”

Citations:
• Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017.
• Ference BA et al. Association of genetic variants related to LDL-C with cardiovascular disease. JAMA. 2016.
• Mensink RP et al. Effects of saturated fatty acids on serum lipids and lipoproteins. Am J Clin Nutr. 2003.
• Clarke R et al. Apolipoprotein B and cardiovascular risk. JAMA. 2020.
• JAMA Network Open. 2021. Ultra-processed food intake in U.S. children

01/06/2026

Watching Peter Attia give rapid-fire longevity takes and pausing where context matters.

• Rapamycin shows its strongest human signal in older adults, mainly immune function. Not proven for younger, healthy people.
• Microplastics matter, but hot exposure is the bigger issue.
• Hormone therapy is still widely misunderstood.
• Testosterone, when used correctly, can be transformative. For women, it is often the most effective treatment for low libido, even when labs look “normal.”

Big levers. Real data. Context over hype.

Educational only. Not medical advice.

01/01/2026

Peptides are here to stay.

Patients are going to explore whether doctors approve or not. Dismissing it doesn’t help anyone.

This space is still new. Limited regulation. Limited trial data. Variable purity and dosing.

That’s exactly why physicians need to get educated, monitor labs, and act as a safety net when complications arise.

Not anti peptide.
Pro guidance.

12/18/2025

Why cholesterol often rises during menopause 👇

Cholesterol is the starting material for estrogen, progesterone, and testosterone.
When estrogen drops, the brain and liver try to compensate.

• Higher FSH signals the ovaries
• The liver increases cholesterol supply
• The ovaries are less responsive

The result is higher cholesterol from a hormone bottleneck, not diet alone.

Save this and share it with someone confused about their labs.

12/15/2025

Address

Ocean Drive & 9th
Miami Beach, FL

Alerts

Be the first to know and let us send you an email when Dr. Joel MD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share